565 related articles for article (PubMed ID: 26459562)
1. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
2. A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils.
Saelices L; Nguyen BA; Chung K; Wang Y; Ortega A; Lee JH; Coelho T; Bijzet J; Benson MD; Eisenberg DS
J Biol Chem; 2019 Apr; 294(15):6130-6141. PubMed ID: 30733338
[TBL] [Abstract][Full Text] [Related]
3. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
[TBL] [Abstract][Full Text] [Related]
4. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
5. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
6. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
7. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.
Klimtchuk ES; Prokaeva T; Frame NM; Abdullahi HA; Spencer B; Dasari S; Cui H; Berk JL; Kurtin PJ; Connors LH; Gursky O
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6428-E6436. PubMed ID: 29941560
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of amyloidogenic segments of human transthyretin.
Saelices L; Sievers SA; Sawaya MR; Eisenberg DS
Protein Sci; 2018 Jul; 27(7):1295-1303. PubMed ID: 29626847
[TBL] [Abstract][Full Text] [Related]
9. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
[TBL] [Abstract][Full Text] [Related]
10. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
Rodrigues JR; Simões CJ; Silva CG; Brito RM
Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol and Sphingomyelin Uniquely Alter the Rate of Transthyretin Aggregation and Decrease the Toxicity of Amyloid Fibrils.
Ali A; Zhaliazka K; Dou T; Holman AP; Kurouski D
J Phys Chem Lett; 2023 Dec; 14(49):10886-10893. PubMed ID: 38033106
[TBL] [Abstract][Full Text] [Related]
12. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
13. Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors.
Guo X; Liu Z; Zheng Y; Li Y; Li L; Liu H; Chen Z; Wu L
Drug Des Devel Ther; 2020; 14():1057-1081. PubMed ID: 32210536
[TBL] [Abstract][Full Text] [Related]
14. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
15. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
16. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
Choi S; Reixach N; Connelly S; Johnson SM; Wilson IA; Kelly JW
J Am Chem Soc; 2010 Feb; 132(4):1359-70. PubMed ID: 20043671
[TBL] [Abstract][Full Text] [Related]
17. Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis.
Ferreira N; Saraiva MJ; Almeida MR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875761
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin deposition in familial amyloidotic polyneuropathy.
Saraiva MJ; Magalhaes J; Ferreira N; Almeida MR
Curr Med Chem; 2012; 19(15):2304-11. PubMed ID: 22471982
[TBL] [Abstract][Full Text] [Related]
19. Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.
João Saraiva M; Mendes Sousa M; Cardoso I; Fernandes R
J Mol Neurosci; 2004; 23(1-2):35-40. PubMed ID: 15126690
[TBL] [Abstract][Full Text] [Related]
20. Modeling transthyretin (TTR) amyloid diseases, from monomer to amyloid fibrils.
Criddle RS; Hansen LD; Woodfield BF; Tolley HD
PLoS One; 2024; 19(6):e0304891. PubMed ID: 38843135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
